Lilly’s Q2 revenue growth and margin expansion outpaced expectations, driven by strong volume gains in key products like Mounjaro and Zepbound, pushing the stock up 6.8%. The market clearly rewarded the company’s robust commercial execution and positive pipeline developments.
- Revenue surged 48% year-over-year, fueled primarily by volume growth of Mounjaro, Zepbound, and contributions from Immunology, Oncology, and Neuroscience portfolios.
- Gross margin improved to 86.3%, a 1.3 percentage point increase, reflecting favorable product mix and better production costs.
- U.S. pricing declined 3% overall, or 9% excluding rebate and discount estimate adjustments, but volume growth offset price pressure.
- Non-GAAP EPS rose to $8.38, including $3.03 in acquired intangible asset charges, compared to $6.31 last year (with $0.14 in charges).
- Regulatory and commercial progress included approvals for Ebglyss maintenance dosing, Jaypirca expansions, and Foundayo launches in multiple international markets, supporting future growth prospects.
Community Discussion